Tag archief: English Only

Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients

— Filgotinib 100 mg and 200 mg Plus Methotrexate (MTX) Demonstrated Significantly Higher ACR20/50/70 Responses Than Methotrexate Alone — — Filgotinib Safety Profile Consistent With...

Gilead and Galapagos Announce Filgotinib Meets Primary and Key Secondary Endpoints in the Phase 3 FINCH 1 Rheumatoid Arthritis Study

— Filgotinib 100 mg and 200 mg Doses Demonstrated Significantly Higher ACR20/50/70 Responses than Placebo in Patients with Prior Inadequate Methotrexate Response — — Significant...

Gilead and Galapagos Report Updated Safety Information for Filgotinib in Rheumatoid Arthritis (RA)

— Pooled Interim Phase 3 FINCH Program Data up to 24 Weeks and Phase 2b DARWIN 3 Long-Term Data Add to Evidence Supporting Filgotinib Safety...

Resolutions of the Annual Shareholders’ Meeting of Sartorius AG

GÖTTINGEN, Germany–(BUSINESS WIRE)– At today’s Annual Shareholders’ Meeting in Göttingen, Germany, shareholders granted discharge to the Executive Board and the Supervisory Board and approved the...

Gilead Launches HepConnect Initiative to Reduce Hepatitis C Infections in Greater Appalachia

— Funding will Expand Testing, Harm Reduction Services and Healthcare Infrastructure in States with Highest Infection Rates — — Harm Reduction Coalition Selected as Lead...

Elliott Submits Agenda Item for EDP’s Upcoming AGM

PROVIDES SHAREHOLDERS A DETERMINATIVE VOTE ON CTG’S TAKEOVER BID CLARIFIES EDP’S CURRENT SITUATION AND CHARTS CLEAR PATHWAY FORWARD LISBON, Portugal & LONDON–(BUSINESS WIRE)– Funds advised...

Initial results from the EMPRISE real-world study of empagliflozin compared with DPP-4 inhibitors presented at ACC.19 and AMCP 2019

EMPRISE is an ongoing real-world evidence study in 35,000 people with type 2 diabetes in the US, comparing empagliflozin with DPP-4 inhibitors; initial results based...

ABB publishes 2018 Annual Report

ZURICH, Switzerland–(BUSINESS WIRE)– ABB Ltd has published its 2018 annual report on its website and has filed the annual report on Form 20-F with the...

Ipsen Publishes its 2018 Registration Document

Regulatory News: PARIS–(BUSINESS WIRE)– Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its 2018 Registration Document has been filed with the French “Autorité des Marchés Financiers”...

Gilead to Present New Data From Multiple Liver Disease Research and Development Programs at The International Liver Congress™ 2019

— More Than 35 Abstracts Across NASH, PSC and Viral Hepatitis Reflect Ongoing Commitment to Advancing Liver Disease Research and Patient Care — FOSTER CITY,...

The Ritz-Carlton Yacht Collection to Provide Luxury Connectivity Experience Powered by SES Networks

SES Networks’ Signature Maritime Solution to offer unmatched connectivity at sea aboard custom-built luxury yachts SES Networks will be providing an innovative, fully-managed hybrid broadband...

Takeda Presents New Data at the Endocrine Society’s 2019 Annual Meeting about the Patient Burden and Long-Term Impact of Chronic Hypoparathyroidism

Impact on patient quality of life quantified including long-term renal and cardiovascular complications Final outcomes of 6 year study into continuous use of rhPTH(1-84) shows...

ABB Wins Contract to Power the First Chinese-Built Cruise Vessel

In a historic deal with Shanghai Waigaoqiao Shipbuilding Co., Ltd. (SWS), ABB will supply a comprehensive power and propulsion package for China’s first domestically built...

Technology Leader Pontus Noren To Join GeoSpock’s Board As Company Secures Further £2 Million Investment From Parkwalk Advisors

The unique spatial big data platform that enables companies to access dynamic contextual data visualisation and programmatic analytics appoints new non-executive board member and announces...

Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis

SUMMIT, N.J.–(BUSINESS WIRE)– Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA)...